CDC Recommendations for Treatment of Concurrent Chlamydia and Gonorrhea Infection
Treatment Regimen
Administer a single intramuscular dose of ceftriaxone 500 mg plus doxycycline 100 mg orally twice daily for 7 days to treat both Neisseria gonorrhoeae (any anatomic site) and Chlamydia trachomatis in adults; this is the current CDC‑endorsed first‑line regimen. [1][2]
Reserve a single 1 g oral dose of azithromycin for chlamydia only when 7‑day doxycycline adherence is doubtful (e.g., limited follow‑up, medication intolerance). [1][2]
Alternative Regimens
For patients with a documented cephalosporin allergy: give spectinomycin 2 g intramuscularly as a single dose, which cures ≈ 98 % of urogenital and anorectal gonorrhea but is unreliable for pharyngeal infection. [3][4]
In pregnancy (chlamydia treatment): use either azithromycin 1 g orally once or amoxicillin 500 mg orally three times daily for 7 days; doxycycline and quinolones are contraindicated. [6][7]
Non‑pregnant chlamydia alternatives: a single 1 g oral dose of azithromycin achieves a cure rate of ~ 97 % (comparable to doxycycline), and levofloxacin 500 mg orally daily for 7 days is an alternative; erythromycin base 500 mg four times daily for 7 days is less effective due to gastrointestinal intolerance. [1][7]
Resistance and Antimicrobial Stewardship
Quinolones (ciprofloxacin, ofloxacin, levofloxacin) are no longer recommended for gonorrhea anywhere in the United States because of widespread resistance, especially in patients with recent travel to Asia, the Pacific, Hawaii, or California. [4][5]8
Azithromycin monotherapy for gonorrhea should be avoided: a 2 g dose causes significant gastrointestinal distress and promotes resistance, and a 1 g dose cures only ~ 93 % of infections. [3][6]8
Cefixime is no longer a first‑line option; it provides lower bactericidal activity (≈ 97.4 % cure vs. 99.1 % for ceftriaxone) and is therefore discouraged. [4][2]5
Site‑Specific Considerations
Pharyngeal gonorrhea: ceftriaxone 500 mg IM remains the treatment of choice; spectinomycin is only ~ 52 % effective and should be avoided. 6
All anatomic sites (cervical, urethral, rectal, pharyngeal): the 500 mg ceftriaxone dose is effective across sites. 3
Follow‑Up and Test‑of‑Cure
Routine test‑of‑cure is not required for asymptomatic patients treated with the recommended regimen; however, persistent symptoms should prompt culture with susceptibility testing. [3][6]
All patients should be retested approximately 3 months after therapy because reinfection rates range from 20 % to 42 % in historically observed cohorts. 1
Pregnant patients require a test‑of‑cure 4 weeks after treatment for both infections. 6
Partner Management
All sexual partners within the 60 days preceding symptom onset or diagnosis must be evaluated and treated with the same dual therapy (ceftriaxone + doxycycline), regardless of which infection was documented in the index case. 3
If the last sexual encounter occurred > 60 days before diagnosis, treat the most recent partner. 3
Special Populations
HIV‑positive individuals receive the same regimen as HIV‑negative patients. 6
Pediatric dosing:
Antimicrobial Stewardship Actions
Report any treatment failures to local health departments with culture and susceptibility data to support surveillance efforts. [4][5]
Surveillance through the Gonococcal Isolate Surveillance Project (GISP) informs ongoing updates to these recommendations. [4][5]